Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal.

Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E.

Mult Scler Relat Disord. 2019 Jan;27:383-390. doi: 10.1016/j.msard.2018.11.022. Epub 2018 Nov 20.

PMID:
30502644
2.

Cannabidiol affects circadian clock core complex and its regulation in microglia cells.

Lafaye G, Desterke C, Marulaz L, Benyamina A.

Addict Biol. 2018 Oct 11. doi: 10.1111/adb.12660. [Epub ahead of print]

PMID:
30307084
3.

A Brief Background on Cannabis: From Plant to Medical Indications.

Klumpers LE, Thacker DL.

J AOAC Int. 2018 Aug 23. doi: 10.5740/jaoacint.18-0208. [Epub ahead of print]

PMID:
30139415
4.

Effectiveness of Raw, Natural Medical Cannabis Flower for Treating Insomnia under Naturalistic Conditions.

Vigil JM, Stith SS, Diviant JP, Brockelman F, Keeling K, Hall B.

Medicines (Basel). 2018 Jul 11;5(3). pii: E75. doi: 10.3390/medicines5030075.

5.

Training and Practices of Cannabis Dispensary Staff.

Haug NA, Kieschnick D, Sottile JE, Babson KA, Vandrey R, Bonn-Miller MO.

Cannabis Cannabinoid Res. 2016 Dec 1;1(1):244-251. doi: 10.1089/can.2016.0024. eCollection 2016.

6.

Cannabidiol in medical marijuana: Research vistas and potential opportunities.

Rong C, Lee Y, Carmona NE, Cha DS, Ragguett RM, Rosenblat JD, Mansur RB, Ho RC, McIntyre RS.

Pharmacol Res. 2017 Jul;121:213-218. doi: 10.1016/j.phrs.2017.05.005. Epub 2017 May 10. Review.

PMID:
28501518
7.

Cannabis, Cannabinoids, and Sleep: a Review of the Literature.

Babson KA, Sottile J, Morabito D.

Curr Psychiatry Rep. 2017 Apr;19(4):23. doi: 10.1007/s11920-017-0775-9. Review.

PMID:
28349316
8.

Cannabidiol: a potential treatment for post Ebola syndrome?

Reznik SE, Gardner EL, Ashby CR Jr.

Int J Infect Dis. 2016 Nov;52:74-76. doi: 10.1016/j.ijid.2016.09.020. Epub 2016 Sep 26.

9.

Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report.

Shannon S, Opila-Lehman J.

Perm J. 2016 Fall;20(4):108-111. doi: 10.7812/TPP/16-005. Epub 2016 Oct 12.

10.

An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.

Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT.

J Pain Symptom Manage. 2013 Aug;46(2):207-18. doi: 10.1016/j.jpainsymman.2012.07.014. Epub 2012 Nov 8.

PMID:
23141881
11.

Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report.

Crippa JA, Hallak JE, Machado-de-Sousa JP, Queiroz RH, Bergamaschi M, Chagas MH, Zuardi AW.

J Clin Pharm Ther. 2013 Apr;38(2):162-4. doi: 10.1111/jcpt.12018. Epub 2012 Oct 24.

PMID:
23095052
12.

Towards the use of non-psychoactive cannabinoids for prostate cancer.

Pacher P.

Br J Pharmacol. 2013 Jan;168(1):76-8. doi: 10.1111/j.1476-5381.2012.02121.x.

13.

Cannabidiol in humans-the quest for therapeutic targets.

Zhornitsky S, Potvin S.

Pharmaceuticals (Basel). 2012 May 21;5(5):529-52. doi: 10.3390/ph5050529.

14.

Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats.

Hsiao YT, Yi PL, Li CL, Chang FC.

Neuropharmacology. 2012 Jan;62(1):373-84. doi: 10.1016/j.neuropharm.2011.08.013. Epub 2011 Aug 16.

PMID:
21867717
15.

Toward drugs derived from cannabis.

Mechoulam R, Carlini EA.

Naturwissenschaften. 1978 Apr;65(4):174-9. Review.

PMID:
351429

Supplemental Content

Loading ...
Support Center